Shares of Keryx Biopharmaceuticals(KERX_) and Aeterna Zentaris(AEZS_) soared March 5 after an article touting the prospects of the drug companies was published on the investor Web site Seeking Alpha. But the credibility of the author, Jeremy Richards, and the veracity of claims and statements made by him, couldn't be verified by anyone at his purported investment firm, the drug companies and Seeking Alpha. Richards is the writer of 14 Seeking Alpha articles over two years promoting Keryx, Aeterna and the experimental cancer drug perifosine that both companies are jointly developing. Richards' latest article on the two stocks was published March 2. Richards called perifosine's Food and Drug Administration approval "practically a done deal" and predicts positive results from an ongoing colon cancer clinical trial.
